Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan Combined With Bevacizumab in mTNBC
NCT07359404Phase 2Enrolling by invitation
- Sponsor
- Yingli Pharma
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Yingli Pharma. Primary endpoints: Progression-Free Survival at 32 months and Incidence and Severity of Adverse Events. Started Apr 2024; status: enrolling by invitation.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07359404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359404.